EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Clinical Interchangeability of PD-L1 Immunohistochemistry Assays in First-Line Non–Small Cell Lung Cancer Management With Cemiplimab

Javier Perez iD, Keith M Kerr, Brian Baker, Fang Fang, Jason Li, Jannine McDonald, Siyu Li, Bo Gao, Jean-Francois Pouliot, Frank Seebach, Israel Lowy, Giuseppe Gullo und 4 weitere

JCO Precision Oncology · 2025

DOI: 10.1200/po-25-00177 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Javier Perez und 15 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals, Inc, Tarrytown, NY. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, B7-H1 Antigen, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Multiple immunohistochemistry (IHC) assays targeting PD-L1 have been developed independently, and a lack of harmonization creates undue complexity for clinicians who use PD-L1 tests to guide treatment decisions. This novel bridging study demonstrates the clinical interchangeability of two PD-L1 IHC assays in first-line treatment of non–small cell lung cancer (NSCLC) with PD-L1 ≥50%. METHODS In the phase III EMPOWER-Lung 1 study (ClinicalTrials.gov identifier: NCT03088540 ), 710 patients were randomly assigned 1:1 to first-line cemiplimab or platinum-doublet chemotherapy for advanced NSCLC with PD-L1 ≥50%, selected by PD-L1 IHC 22C3 pharmDx (Agilent Technologies, Santa Clara, CA). RESULTS A total of 871 patient samples were retrospectively tested using the VENTANA PD-L1 (SP263) assay (Roche Diagnostics, Indianapolis, IN), including 481 enrolled patients and 390 patients who did not pass screening (22C3 PD-L1

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenCarcinoma, Non-Small-Cell LungImmunohistochemistryLung NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedRetrospective Studies

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenCD274 protein, humancemiplimab

Autor:innen und Institutionen

  • Regeneron Pharmaceuticals, Inc, Tarrytown, NY.
  • Aberdeen University Medical School, University of Aberdeen, Aberdeen, United Kingdom.
  • Roche Molecular Systems, Inc, Pleasanton, CA.
  • Roche Tissue Diagnostics, Tucson, AZ.

ORCID-Profile: Javier Perez, Jennifer Hamilton

Zitieren

APA

Perez, J., Kerr, K. M., Baker, B., Fang, F., Li, J., McDonald, J., Li, S., Gao, B., Pouliot, J. F., Seebach, F., Lowy, I., Gullo, G., Herman, G., Hamilton, J., Rietschel, P., & McGuire, K. (2025). Clinical Interchangeability of PD-L1 Immunohistochemistry Assays in First-Line Non–Small Cell Lung Cancer Management With Cemiplimab. JCO Precision Oncology. https://doi.org/10.1200/po-25-00177

Vancouver

Perez J, Kerr KM, Baker B, Fang F, Li J, McDonald J, et al. Clinical Interchangeability of PD-L1 Immunohistochemistry Assays in First-Line Non–Small Cell Lung Cancer Management With Cemiplimab. JCO Precision Oncology. 2025. doi:10.1200/po-25-00177

BibTeX
@article{Perez2025,
  author = {Perez, Javier and Kerr, Keith M and Baker, Brian and Fang, Fang and Li, Jason and McDonald, Jannine and Li, Siyu and Gao, Bo and Pouliot, Jean-Francois and Seebach, Frank and Lowy, Israel and Gullo, Giuseppe and Herman, Gary and Hamilton, Jennifer and Rietschel, Petra and McGuire, Kristina},
  title = {Clinical Interchangeability of PD-L1 Immunohistochemistry Assays in First-Line Non–Small Cell Lung Cancer Management With Cemiplimab},
  journal = {JCO Precision Oncology},
  year = {2025},
  doi = {10.1200/po-25-00177}
}
Kostenlos starten →